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Abstract: Post-transplantation histoplasmosis may be acquired via
inhalation, may result from endogenous reactivation, or may be
derived from the allograft. The Histoplasma and Aspergillus
enzyme-linked immunoassays are increasingly being relied upon
for rapid diagnosis of fungal infections, especially in
immunocompromised patients. We describe 4 cases of solid organ
transplant recipients who had histoplasmosis and a falsely positive
Aspergillus galactomannan (GM) obtained from the serum or
bronchoalveolar lavage (BAL) fluid. We also report our
experience, testing for Histoplasma antigen (Ag) in specimens
positive for Aspergillus GM. From January 2007 through
December 2010, of 2432 unique patients who had positive
Aspergillus GM tests, 514 (21%) were tested for Histoplasma Ag,
and 27 were found to be positive. Most specimens that tested
positive for both Aspergillus and Histoplasma were obtained by
BAL. False-positive tests for Aspergillus GM can occur in
immunosuppressed patients who have histoplasmosis, and may
obscure the correct diagnosis.
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Histoplasmosis is a disease endemic in the Mississippi
and Ohio River valleys, Central America, several
countries in South America, and parts of Asia and
Africa. Post-transplantation histoplasmosis is relatively
uncommon even in these endemic areas (1). Infection
may be acquired via inhalation from the environment,
may result from endogenous reactivation in the set-
ting of immunosuppression, or may be derived from
the allograft. The diagnosis is established by microbi-
ologic or histopathologic evidence of fungal infection.
The Histoplasma enzyme-linked immunoassay (EIA)
can detect antigen (Ag) in serum, urine, bronchoalve-
olar lavage (BAL) fluid, or cerebrospinal fluid, and
has become a useful diagnostic tool, especially in
immunosuppressed patients (2).
Galactomannan (GM), a heat-stable polysaccharide
present in the cell wall of most fungi, is released dur-
ing fungal growth in the host. The Platelia Aspergillus
EIA detects a circulating GM Ag produced by Asper-
gillus species and a few other fungi. False-positive
results of the assay have been reported after exposure
to semisynthetic penicillins, such as amoxicillin and
piperacillin, derived from molds of the genus Penicil-
lium. Cross-reactivity between the Aspergillus GM and
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Histoplasma Ag has also been observed (3). Herein,
we describe 4 patients with histoplasmosis, initially
misdiagnosed as aspergillosis, because of a falsely
positive Aspergillus GM assay. We also review
whether testing for Histoplasma Ag was requested on
specimens sent to MiraVista Diagnostics that were
positive for the Aspergillus GM.
Case reports
Case 1
A 60-year-old woman from Minnesota with autoim-
mune hepatitis and cirrhosis underwent deceased-
donor liver transplantation in 2009. She developed
diarrhea followed by fevers and hypoxia, 1 month
after transplantation. Chest x-ray (CXR) showed bilat-
eral interstitial infiltrates. She progressed to respiratory
failure, requiring mechanical ventilation. Histoplasma
capsulatum was recovered from blood cultures and
BAL specimens; BAL fluid did not yield Aspergillus
species. Urine Histoplasma Ag was markedly elevated
(>39 ng/mL). Serum Aspergillus GM was positive at an
optical density index of 2.6. The patient responded to
treatment with liposomal amphotericin B (L-AmB),
which was later changed to itraconazole.
The patient was found to have moderate to severe
acute cellular rejection of the allograft, 7 months after
transplantation, which was refractory to corticoster-
oids. Therefore, the patient received anti-thymocyte
globulin. She went on to develop chronic allograft
rejection with progressive hepatic failure and worsen-
ing renal function. Chest computed tomography (CT)
scan demonstrated a 2.5 cm rounded nodule and an
adjacent nodular infiltrate. In BAL fluid, the Aspergil-
lus GM index was positive at 0.55 (cutoff for positivity:
0.5) and this was concerning for aspergillosis. The
Histoplasma Ag was markedly elevated at 29.63 ng/mL.
Small pleomorphic yeasts were seen on fungal smear,
but H. capsulatum did not grow in culture. The serum
itraconazole level was undetectable. Antifungal treat-
ment was changed to L-AmB, which she received for
6 weeks. She underwent successful combined liver
and kidney transplantation, 10 months after the first
transplant. Treatment was eventually stepped down to
itraconazole in liquid form.
Case 2
A 25-year-old woman from Michigan with renal failure
precipitated by meningococcal meningitis underwent
a living-donor renal transplantation in 2005. She devel-
oped fever associated with frontal headache, 2 years
after transplantation. Chest CT scan showed a small
nodule in the right upper lobe surrounded by ground-
glass opacities. After initiating empirical antimicrobial
treatment, she developed increasing dyspnea, and
CXR showed diffuse pulmonary infiltrates. She eventu-
ally required mechanical ventilation. Serum Aspergillus
GM index was 3.03, and she was started on vorico-
nazole and micafungin for possible aspergillosis.
However, urine Histoplasma Ag was >39 ng/mL, and
later blood and BAL cultures yielded H. capsulatum;
BAL fluid did not grow Aspergillus species.
L-AmB was started, and the patient was able to be
extubated on hospital day 11. Antifungal treatment
was changed to itraconazole. The patient com-
pleted 18 months of treatment without recurrence of
disease.
Case 3
A 40-year-old woman from Nebraska with a history of
alcoholic cirrhosis underwent living-donor liver trans-
plantation in 2009. The patient presented with fevers,
tachycardia, shortness of breath, and a right-sided
pleural effusion, 3 weeks post transplant. Chest CT
scan showed multifocal nodular consolidation through-
out the lungs. Pleural fluid grew viridans Streptococcus
and Candida albicans. The patient remained febrile.
The BAL Aspergillus GM index was 4.49, with a nega-
tive serum GM. The BAL Histoplasma Ag was >39 ng/
mL. The BAL fluid grew H. capsulatum and never
showed Aspergillus. The patient was treated with vori-
conazole for 12 months because of concern for possible
concomitant invasive pulmonary aspergillosis, and her
disease resolved.
Case 4
A 60-year-old man from Illinois with end-stage renal
disease due to focal segmental glomerulosclerosis
underwent living-donor renal transplantation in 2008.
This was his second renal transplant. He presented
with a febrile illness 2 years later. Physical exam was
notable for new symmetric polyarthritis. Chest CT
scan showed diffuse bilateral interstitial infiltrates.
Serum Aspergillus GM index was 8.61. As the patient
had recently received high-dose steroids, the diagno-
sis of invasive aspergillosis was considered likely, and
voriconazole was begun. The BAL fluid yielded
H. capsulatum, but no Aspergillus species. The urine
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Histoplasma Ag was 25 ng/mL and the serum Ag was
19.4 ng/mL. The patient initially responded to vorico-
nazole, but then had recurrent fever, and therapy was
changed to L-AmB for 4 weeks, followed by itraco-
nazole.
Methods
The cases described had clinical signs and symptoms
attributed to fungal infection and positive culture for
H. capsulatum. Specimens stored at 20°C at Mira-
Vista Diagnostics in Indianapolis were tested with the
Platelia Aspergillus GM EIA and the Histoplasma Ag
EIA (4). As of February 2010, for both assays, serum
specimens were pretreated with EDTA at 100°C
for 6 min. The BAL specimens were pretreated for
the Aspergillus GM EIA only. Urine specimens were
not pretreated. Results of Aspergillus GM testing from
January 1, 2007 through December 31, 2010 were
reviewed to determine if testing for Histoplasma Ag
was requested by the ordering practitioners on speci-
mens that were positive for Aspergillus GM. We then
identified the proportion of specimens containing
Aspergillus GM that were also positive for Histoplasma
Ag.
Results
Demographic characteristics, Ag levels, and culture
results of the reported cases are summarized in
Table 1. As shown in Table 2, of 2432 unique patients
who had positive Aspergillus GM tests from January
2007 through December 2010, 514 (21%) were tested
for Histoplasma Ag, and 27 were found to be positive.
Sixteen of the positive samples were BAL specimens
and 11 were serum specimens. A follow-up serum
specimen for Aspergillus GM was submitted within
4 days of the initial serum specimen in 1 patient and
was also positive: initial, 7.7 index units; follow-up, 6.5
index units. Among patients with negative Histoplasma
Ag, the median Aspergillus GM index was 1.4 units
(range, 0.5–11.9). In those with positive Histoplasma
Ag, the median serum Aspergillus GM index was 3.2
units (range, 0.7–10.9) (P = 0.096).
The number of patients who had tests performed in
both assays, increased from 15% in 2007 to 25% in
2010. More specifically, in 2010, 10 patients, separate
from those reported herein, had positive results for
both assays. Nine had a positive BAL Aspergillus GM
and 1 had a positive serum GM. Urine Histoplasma
Ag was positive in 7 specimens, serum Ag in 6 speci-
mens, and BAL Ag in 5 specimens. Three patients
were stated to have histoplasmosis and did not have
aspergillosis, 1 had dual infection with both Histoplas-
ma and Aspergillus, and 1 had blastomycosis. In the 5
other cases, further clinical data were unavailable.
Discussion
Our report illustrates that false-positive results for
Aspergillus GM in serum or BAL fluid can lead to a
mistaken diagnosis of aspergillosis in solid organ
transplant recipients who have histoplasmosis. No
other causes of false positivity, such as exposure to
amoxicillin or piperacillin, were identified in the
reported cases. False-positive reactions for Aspergillus
GM have been shown to occur twice as often in speci-
mens that have Histoplasma Ag levels of >39 ng/mL
(3), as was noted in 3 patients in this report. Major
Demographic characteristics, antigen levels, and culture results in the reported cases
Age, gender
Histoplasma Ag*
(ng/mL), serum
Histoplasma Ag*
(ng/mL), urine
Histoplasma Ag*
(ng/mL), BAL
Aspergillus GM**
(OD index), serum
Aspergillus GM**
(OD index), BAL
Growth of Histoplasma
capsulatum in culture
60 F ND >39 ND 2.60 ND Blood, BAL
<0.6 2.36 29.63 Negative 0.55 No growth
25 F ND >39 ND 3.03 6.20 Blood, BAL
40 F Negative 18.75 >39 Negative 4.49 BAL
60 M 19.4 25.0 ND 8.61 ND BAL
*For Histoplasma Ag: <0.6–3.9 ng/mL is low positive; 4.0–19.9 ng/mL is moderately positive; 20.0 to >39 ng/mL is highly positive.
**For Aspergillus GM: Cutoff for positivity is 0.5.
Ag, antigen; BAL, bronchoalveolar lavage fluid; GM, galactomannan; OD, optical density; ND, not done.
Table 1
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differences between the 2 fungi in the chemical struc-
ture of the galactofuranose side chains of the GM (5)
explain why high concentrations of Histoplasma Ag
are required for cross-reactivity. The Aspergillus GM
index, however, was not significantly different in
patients who had a negative Histoplasma Ag test when
compared with those who had a positive Histoplasma
Ag test.
Cross-reactivity between Histoplasma Ag and Asper-
gillus GM has been described in experimental animal
models (3). Few reports have documented a positive
reaction for Aspergillus GM in immunosuppressed
patients with disseminated histoplasmosis (6–8). False
positivity of the Aspergillus GM has also been
described in blastomycosis (9), cryptococcosis (10),
coccidioidomycosis (L.J. Wheat, unpublished data),
paracoccidioidomycosis (11), and infection due to
Penicillium marneffei (12) and Geotrichum capitatum
(13).
Cross-reactivity in the Histoplasma Ag assay can
occur in infections due to other endemic fungi, such
as Paracoccidioides brasiliensis, P. marneffei, Blasto-
myces dermatitidis (14), and Coccidioides immitis (15).
Notably, Histoplasma and Blastomyces Ags are immu-
nologically identical. In this report, 1 patient with blas-
tomycosis had a falsely positive Histoplasma Ag assay,
as has been previously described (16). In most dual-
tested cases, we do not have further data and some of
these may have been caused by endemic mycoses
other than histoplasmosis.
No false-positive Histoplasma Ag measured in urine
or serum has been reported in patients who had
invasive aspergillosis. Presumably, this is a result of
the low level of circulating GM in these patients in
comparison with the high level of circulating Histo-
plasma Ag in patients with disseminated histoplas-
mosis. However, in regard to BAL fluid, a stronger
possibility of a falsely positive exists for Histoplasma
Ag assay occurring in a patient who actually has inva-
sive pulmonary aspergillosis. In a study of 60 BAL
fluid specimens positive for Aspergillus GM, 5 were
also positive in the Histoplasma Ag assay, but all at
values <0.6 ng/mL (17). The sensitivity of the Histo-
plasma Ag assay in BAL fluid was estimated to be
93.5% and the specificity 97.8%.
H. capsulatum may take as long as 4 weeks to grow
in the laboratory. Results of Ag testing are available
within days after collection of the specimen. Increas-
ingly, Ag testing is relied upon for rapid diagnosis of
fungal infections. When cross-reactivity occurs in non-
culture-based tests, this can create confusion,
as occurred in the cases presented in this report.
Although rare, dual infection with both Histoplasma
and Aspergillus is possible and should be considered in
the appropriate clinical setting. In all patients, culture
and histopathologic evidence for specific fungal organ-
isms remain important for definitive diagnosis.
Despite prior recognition of cross-reactivity and rec-
ommendations to exclude histoplasmosis in patients
with positive results for Aspergillus GM (3), Histoplasma
Ag testing was only performed for 21% of such cases.
Notably, a modest year-to-year increase was observed
in requests for Histoplasma Ag testing in specimens
positive for Aspergillus GM (Table 2). This level of
testing can be further improved as more practitioners
become aware of the cross-reactivity between the 2
assays. Differentiating between the 2 disease entities
has important treatment implications, especially when
it comes to alternative therapeutic agents. Echinocan-
dins, which can be used in the treatment of invasive
aspergillosis, are not active against H. capsulatum,
and the effectiveness of voriconazole has not been
established for histoplasmosis (18).
In conclusion, these findings indicate that cross-
reactivity of Aspergillus GM and Histoplasma Ag can
lead to false-positive Aspergillus EIA in patients who
actually have histoplasmosis. Especially in immuno-
suppressed patients with diffuse pulmonary infiltrates
and a relevant epidemiologic history, it is important to
test for Histoplasma Ag, as well as Aspergillus GM, in
serum and BAL fluid.
Testing for Histoplasma antigen in samples that had a positive
Aspergillus galactomannan assay
Year 2007 2008 2009 2010 Total
Number of
patients with
positive
Aspergillus GM
246 433 729 1024 2432
Number of
patients with
positive
Aspergillus GM
tested for
Histoplasma Ag
38
(15%)
80
(18%)
140
(19%)
256
(25%)
514
(21%)
Number of
patients with
positive
Aspergillus GM
and Histoplasma
Ag
4
(11%)
5
(6%)
8
(6%)
10
(4%)
27
(5%)
GM, galactomannan; Ag, antigen.
Table 2
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